دورية أكاديمية
أعرض في EDS

Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry.

التفاصيل البيبلوغرافية
العنوان: Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry.
المؤلفون: Ferreiro-Iglesias R; Fundación Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS), Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain., Porto Silva S; Fundación Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS), Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain., Marín S; UCO, IMIBIC, Hospital Universitario Reina Sofía, Córdoba, Spain., Casanova MJ; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Madrid, Spain., Mañosa M; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain., González-Muñoza C; Hospital Santa Creu i Sant Pau, Institut d'Investigacions Biomèdiques (IIB) Sant Pau, Barcelona, Spain., de Francisco R; Hospital Universitario Central de Asturias, and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain., Caballol B; CIBERehd. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain., Arias L; Hospital Universitario de Burgos, Burgos, Spain., Piqueras M; Consorci Sanitari de Terrassa CST, Barcelona, Spain., Zabana Y; CIBERhed, Hospital Universitari Mutua Terrassa, Barcelona, Spain.; Universitat Autónoma de Barcelona, Barcelona, Spain., Rivero M; Grupo de Investigación Clínica y Traslacional en Enfermedades Digestivas, Instituto de Investigación Valdecilla (IDIVAL), Hospital Universitario Marqués de Valdecilla, Santander, Spain., Calvet X; Universitat Autónoma de Barcelona, Barcelona, Spain.; CIBERehd, Institut d'Investigació i Innovació Parc Taulí, Departament de Medicina. Parc Taulí, Hospital Universitari, Sabadell, Spain., Mesonero F; Universidad de Alcalá de Henares, Hospital Universitario Ramón y Cajal, Madrid, Spain., Varela Trastoy P; Hospital Universitario de Cabueñes, Gijón, Spain., Busta Nistal R; Hospital Clínico Universitario de Valladolid, Valladolid, Spain., Gómez Perosanz R; Hospital Universitario Fundación Alcorcón, Madrid, Spain., Vega P; Complexo Hospitalario Universitario de Ourense, Ourense, Spain., Gonzalez-Vivo M; IMIM Hospital del Mar Medical Research Institute, Hospital del Mar, Barcelona, Spain., Iborra M; Hospital Universitario y Politécnico La Fe, Valencia, Spain., Bermejo F; Hospital Universitario de Fuenlabrada e Instituto de Investigación Sanitaria La Paz (IdiPAZ), Madrid, Spain., Madero L; CIBERehd. Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain., Rodríguez-Lago I; Hospital Universitario de Galdakao, Biobizkaia Health Research Institute, Galdakao, Spain., Rodríguez Gonzalez M; Hospital de Ciudad Real, Ciudad Real, Spain., Vera I; Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain., Ponferrada Díaz Á; Hospital Universitario Infanta Leonor, Madrid, Spain., Vela M; Hospital Nuestra señora de la Candelaria, Tenerife, Spain., Torrealba Medina L; Hospital Dr. Josep Treuta, Girona, Spain., Van Domselaar M; Hospital Universitario de Torrejón, Madrid, Spain., Gomollón F; CIBERehd. Hospital Clínico Universitario Lozano Blesa, Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain., Iglesias E; UCO, IMIBIC, Hospital Universitario Reina Sofía, Córdoba, Spain., Gisbert JP; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Madrid, Spain., Calafat M; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain., Giordano A; Hospital Santa Creu i Sant Pau, Institut d'Investigacions Biomèdiques (IIB) Sant Pau, Barcelona, Spain., Pérez-Martínez I; Hospital Universitario Central de Asturias, and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain., Ricart E; CIBERehd. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain., Sicilia B; Hospital Universitario de Burgos, Burgos, Spain., Mena R; Consorci Sanitari de Terrassa CST, Barcelona, Spain., Esteve M; CIBERhed, Hospital Universitari Mutua Terrassa, Barcelona, Spain., Rivas C; Universitat Autónoma de Barcelona, Barcelona, Spain., Brunet-Mas E; CIBERehd, Institut d'Investigació i Innovació Parc Taulí, Departament de Medicina. Parc Taulí, Hospital Universitari, Sabadell, Spain., Fernández C; Universidad de Alcalá de Henares, Hospital Universitario Ramón y Cajal, Madrid, Spain., de Jorge Turrión MÁ; Hospital Universitario de Cabueñes, Gijón, Spain., Velayos Jiménez B; Hospital Clínico Universitario de Valladolid, Valladolid, Spain., Quiñones Calvo M; Hospital Universitario Fundación Alcorcón, Madrid, Spain., Regueiro Expósito C; Complexo Hospitalario Universitario de Ourense, Ourense, Spain., Márquez-Mosquera L; IMIM Hospital del Mar Medical Research Institute, Hospital del Mar, Barcelona, Spain., Nos P; Hospital Universitario y Politécnico La Fe, Valencia, Spain., Granja A; Hospital Universitario de Fuenlabrada e Instituto de Investigación Sanitaria La Paz (IdiPAZ), Madrid, Spain., Gutiérrez A; CIBERehd. Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain., Cabriada JL; Hospital Universitario de Galdakao, Biobizkaia Health Research Institute, Galdakao, Spain., Hervías Cruz D; Hospital de Ciudad Real, Ciudad Real, Spain., Calvo M; Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain., Pérez Pérez J; Hospital Universitario Infanta Leonor, Madrid, Spain., Rodríguez Díaz Y; Hospital Nuestra señora de la Candelaria, Tenerife, Spain., Busquets Casal D; Hospital Dr. Josep Treuta, Girona, Spain., Menacho M; Hospital Joan XXIII Tarragona, Tarragona, Spain., Leal C; Universitat Central de Catalunya. Consorci Hospitalari de Vic. Universitat de Vic, Barcelona, Spain., Lucendo AJ; Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Hospital General de Tomelloso, Ciudad Real, Spain., Royo V; Hospital Universitario Son Espases, Palma, Spain., Olivares S; Hospital Universitario 12 de Octubre, Madrid, Spain., Álvarez Herrero B; Hospital Universitario de Álava, Álava, Spain., Carrillo-Palau M; Hospital Universitario de Canarias, Gran Canaria, Spain., Gilabert Álvarez P; Hospital de Viladecans, Barcelona, Spain., Manceñido Marcos N; Hospital Universitario Infanta Sofía, Madrid, Spain., Martínez-Pérez TJ; Hospital Virgen de la Luz de Cuenca, Cuenca, Spain., Muñoz Villafranca MC; Hospital de Basurto, Bilbao, Spain., Almela P; Hospital General Universitario de Castellón, Castellón, Spain., Argüelles-Arias F; Universidad de Sevilla, Hospital Universitario Virgen Macarena, Sevilla, Spain., Legido J; Complejo Asistencial de Segovia, Segovia, Spain., Fuentes Coronel AM; Complejo Asistencial de Zamora, Zamora, Spain., Nieto L; Fundación Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS), Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain., Domènech E; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.; Universitat Autónoma de Barcelona, Barcelona, Spain., Barreiro-de Acosta M; Fundación Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS), Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.
مؤلفون مشاركون: ENEIDA project sponsored by GETECCU
المصدر: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2024 Sep; Vol. 60 (5), pp. 604-612. Date of Electronic Publication: 2024 Jun 28.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2036 (Electronic) Linking ISSN: 02692813 NLM ISO Abbreviation: Aliment Pharmacol Ther Subsets: MEDLINE
أسماء مطبوعة: Publication: Oxford : Wiley-Blackwell
Original Publication: [Oxford, OX] : Blackwell Scientific Publications, [c1987-
مواضيع طبية MeSH: Registries* , Proctitis*/drug therapy , Colitis, Ulcerative*/drug therapy , Immunosuppressive Agents*/therapeutic use, Humans ; Male ; Female ; Middle Aged ; Adult ; Aged ; Prospective Studies
مستخلص: Background: Ulcerative proctitis (UP) can have a milder, less aggressive course than left-sided colitis or extensive colitis. Therefore, immunosuppressants tend to be used less in patients with this condition. Evidence, however, is scarce because these patients are excluded from randomised controlled clinical trials. Our aim was to describe the characteristics of patients with refractory UP and their disease-related complications, and to identify the need for immunosuppressive therapies.
Methods: We identified patients with UP from the prospective ENEIDA registry sponsored by the GETECCU. We evaluated socio-demographic data and complications associated with immunosuppression. We defined immunosuppression as the use of immunomodulators, biologics and/or small molecules. We used logistic regression to identify factors associated with immunosuppressive therapy.
Results: From a total of 34,716 patients with ulcerative colitis, we identified 6281 (18.1%) with UP; mean ± SD age 53 ± 15 years, average disease duration of 12 ± 9 years. Immunosuppression was prescribed in 11% of patients, 4.2% needed one biologic agent and 1% needed two; 2% of patients required hospitalisation, and 0.5% underwent panproctocolectomy or subtotal colectomy. We identified 0.2% colorectal tumours and 5% extracolonic tumours. Patients with polyarthritis (OR 3.56, 95% CI 1.86-6.69; p < 0.001) required immunosuppressants.
Conclusions: Among patients with refractory UP, 11% required immunosuppressant therapy, and 4.2% required at least one biologic agent.
(© 2024 John Wiley & Sons Ltd.)
References: Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease controversies, consensus, and implications. Gut. 2006;55:749–753.
Shivananda S, Lennard‐Jones J, Logan R, Fear N, Price A, Carpenter L, et al. Incidence of inflammatory bowel disease across Europe is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC‐IBD). Gut. 1996;39:690–697.
Chaparro M, Garre A, Núñez Ortiz A, Diz‐Lois Palomares MT, Rodríguez C, Riestra S, et al. Incidence, clinical characteristics and management of inflammatory bowel disease in Spain: large‐scale epidemiological study. J Clin Med. 2021;10:2885.
Danish 5‐ASA Group. Topical 5‐aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. A randomized, double‐blind multicenter trial. Dig Dis Sci. 1987;32:598–602.
Calafat M, Lobaton T, Mañosa M, Marín M, Caballero N, Larrain M, et al. Therapeutic requirements in active ulcerative proctitis: a single‐centre study. Gastroenterol Hepatol. 2017;40:663–668.
Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16:2–17.
Pineton De Chambrun G, Tassy B, Kollen L, Dufour G, Valats J‐C, Bismuth M, et al. The treatment of refractory ulcerative colitis. Best Pract Res Clin Gastroenterol. 2018;32–33:49–57.
Dubois E, Moens A, Geelen R, Sabino J, Ferrante M, Vermeire S. Long‐term outcomes of patients with ulcerative proctitis: analysis from a large referral centre cohort. United European Gastroenterol J. 2020;8:933–941.
Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, et al. Third European evidence‐based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11:769–784.
Nedelciuc O, Pintilie I, Dranga M, Mihai CPC, Prelipcean CC. Quality of life in patients with ulcerative colitis. Rev Med Chir Soc Med Nat Iasi. 2012;116:756–760.
Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.
Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate‐to‐severe ulcerative colitis. Gastroenterology. 2012;142:257–265.
Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab maintains clinical response in patients with moderate‐to‐severe ulcerative colitis. Gastroenterology. 2014;146:96–109.
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.
Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–1736.
Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201–1214.
Ginard D, Marín‐Jiménez I, Barreiro‐de Acosta M, Ricart E, Domènech E, Gisbert JP, et al. Recommendations of the Spanish Working Group on Crohn's disease and ulcerative colitis (GETECCU) on topical therapy in ulcerative colitis. Gastroenterol Hepatol. 2020;43:97–105.
Zabana Y, Panés J, Nos P, Gomollón F, Esteve M, García‐Sánchez V, et al. The ENEIDA registry (Nationwide study on genetic and environmental determinants of inflammatory bowel disease) by GETECCU: design, monitoring and functions. Gastroenterol Hepatol. 2020;43:551–558.
Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro‐de Acosta M, et al. Third European evidence‐based consensus on diagnosis and Management of Ulcerative Colitis. Part 1: definitions, diagnosis, extra‐intestinal manifestations, pregnancy, cancer surveillance, surgery, and Ileo‐anal pouch disorders. J Crohns Colitis. 2017;11:649–670.
Pineton de Chambrun G, Amiot A, Bouguen G, Viennot S, Altwegg R, Louis E, et al. Efficacy of tumor necrosis factor antagonist treatment in patients with refractory ulcerative proctitis. Clin Gastroenterol Hepatol. 2020;18:620–627.
Bouguen G, Roblin X, Bourreille A, Feier L, Filippi J, Nancey S, et al. Infliximab for refractory ulcerative proctitis. Aliment Pharmacol Ther. 2010;31:1178–1185.
Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First‐ and second‐line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta‐analysis. Clin Gastroenterol Hepatol. 2020;18:2179–2191.
Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, et al. Effectiveness and safety of vedolizumab and anti‐TNF naïve patients with inflammatory bowel disease. A multicenter retrospective European study. Inflamm Bowel Dis. 2018;24:2442–2451.
Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, et al. Vedolizumab for ulcerative colitis. Treatment outcomes from the VICTORY consortium. Am J Gastroenterol. 2018;113:1345–1354.
Lawrance IC, Copeland TS. Rectal tacrolimus in the treatment of resistant ulcerative proctitis. Aliment Pharmacol Ther. 2008;28:1214–1220.
van Dieren JM, van Bodegraven AA, Kuipers EJ, Bakker EN, Poen AC, van Dekken H, et al. Local application of tacrolimus in distal colitis: feasible and safe. Inflamm Bowel Dis. 2009;15:193–198.
Jaeger SU, Klag T, Hoeger K, Klumpp S, Escher M, Malek N, et al. Tacrolimus suppositories in therapy‐resistant ulcerative proctitis. Inflamm Intest Dis. 2019;3:116–124.
Hoie O, Wolters FL, Riis L, Bernklev T, Aamodt G, Clofent J, et al. European Collaborative Study Group of Inflammatory Bowel Disease. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007;132:507–515.
Barreiro‐de Acosta M, Magro F, Carpio D, Lago P, Echarri A, Cotter J, et al. Ulcerative colitis in the north of Portugal and Galicia in Spain. Inflamm Bowel Dis. 2010;16:1227–1238.
Michalopoulos G, Karmiris K. When disease extent is not always a key parameter: management of refractory ulcerative proctitis. Curr Res Pharmacol Drug Discov. 2021;11(3):100071.
Dias CC, Rodrigues PP, da Costa‐Pereira A, Magro F. Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta‐analysis of cohort studies. J Crohns Colitis. 2015;9:156–163.
Nicolaides S, Vasudevan A, Long T, van Langenberg D. The impact of tobacco smoking on treatment choice and efficacy in inflammatory bowel disease. Intest Res. 2021;19:158–170.
Gordon H, Biancone L, Fiorino G, Katsanos KH, Kopylov U, Sulais EA, et al. ECCO guidelines on inflammatory bowel disease and malignancies. J Crohn's Colitis. 2023;17:827–854.
Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population‐based study. N Engl J Med. 1990;323:1228–1233.
Zhou Q, Shen ZF, Wu BS, Xu CB, He ZQ, Chen T, et al. Risk of colorectal cancer in ulcerative colitis patients: a systematic review and meta‐analysis. Gastroenterol Res Pract. 2019;2019:5363261.
المشرفين على المادة: 0 (Immunosuppressive Agents)
تواريخ الأحداث: Date Created: 20240629 Date Completed: 20240813 Latest Revision: 20240813
رمز التحديث: 20240813
DOI: 10.1111/apt.18133
PMID: 38943230
قاعدة البيانات: MEDLINE
الوصف
تدمد:1365-2036
DOI:10.1111/apt.18133